[The efficacy and safety of bortezomib, pomalidomide and dexamethasone regimen in the treatment of relapsed/refractory multiple myeloma].

Wang, J; Xu, H; Chu, X X; Wang, W

Wang, J; Xu, H; Chu, X X; Wang, W.

Afiliação

Wang J; Hematology Department, The Affiliated Hospital of Qingdao University, Qingdao 266000, China.
Xu H; Hematology Department, The Affiliated Hospital of Qingdao University, Qingdao 266000, China.
Chu XX; Hematology Department, Yantai Yuhuangding Hospital, Yantai 264000, China.
Wang W; Hematology Department, The Affiliated Hospital of Qingdao University, Qingdao 266000, China.

Zhonghua Xue Ye Xue Za Zhi ; 44(7): 602-605, 2023 Jul 14.

Article em Zh | MEDLINE | ID: mdl-37749045

Assuntos

Mieloma Múltiplo; Humanos; Mieloma Múltiplo/tratamento farmacológico; Bortezomib/uso terapêutico; Talidomida/uso terapêutico; Dexametasona/uso terapêutico

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Mieloma Múltiplo Limite: Humans Idioma: Zh Revista: Zhonghua Xue Ye Xue Za Zhi Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google